Last reviewed · How we verify
TRx0014
At a glance
| Generic name | TRx0014 |
|---|---|
| Sponsor | TauRx Therapeutics Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Open Label Study of TRx0014 in Alzheimer's Disease (PHASE2)
- Comparative Bioavailability in Healthy Elderly Volunteers (PHASE1)
- TRx0014 in Patients With Mild or Moderate Alzheimer's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TRx0014 CI brief — competitive landscape report
- TRx0014 updates RSS · CI watch RSS
- TauRx Therapeutics Ltd portfolio CI